Windtree Therapeutics Allocates $700M to Buy BNB After Token Hits All-Time High Stock Dips 5%

Nasdaq-listed Windtree Therapeutics has announced a $700 million allocation to purchase BNB, the native cryptocurrency of the Binance blockchain, following the token’s recent all-time high price. The biotech firm, headquartered in Warrington, Pennsylvania, revealed the plan on June 28, 2025, after BNB reached $808, surpassing its previous record. The acquisition will be funded through a $500 million equity line of credit with an unnamed institutional investor and a $20 million stock-purchase agreement with Build and Build Corp. Windtree also partnered with Kraken to custody the BNB tokens, emphasizing long-term reserve holdings rather than immediate operational use [1].

The company’s CEO, Jed Latkin, highlighted the strategic importance of securing additional capital to expand BNB purchases, pending stockholder approval. Windtree previously committed $200 million to the cryptocurrency, and the new plan represents a significant escalation in its crypto treasury strategy. The firm’s stock, which has risen 162% over the past month, dipped 5% following the announcement [1].

BNB, with a $106.9 billion market cap, has seen renewed institutional interest. The token was trading at $769 on CoinGecko, down from its peak but still reflecting strong demand. Windtree’s move aligns with a broader trend of publicly traded companies investing in cryptocurrencies to diversify balance sheets and hedge against traditional market risks. Strategy (formerly MicroStrategy), the first major firm to adopt a Bitcoin treasury strategy, now holds 607,770 BTC ($70.6 billion), while others like Semler Scientific and Metaplanet have also entered the space [1].

Other biotech firms are following suit. Liminatus Pharma, a separate entity, secured $520 million in funding for BNB investments, though specifics remain unclear [2]. This trend raises questions about regulatory clarity, particularly in the U.S., where the SEC has yet to establish definitive guidelines for corporate crypto holdings. Critics argue that such moves could expose firms to volatility risks and regulatory scrutiny, given the pharmaceutical sector’s reliance on stable, long-term R&D funding [1].

Windtree’s decision to allocate a substantial portion of its capital to BNB has sparked mixed reactions. Proponents view it as a bold endorsement of crypto’s institutional legitimacy, while skeptics caution against the mismatch between crypto’s volatility and the biotech industry’s capital needs. The firm has not disclosed specific applications for the BNB beyond its role as a reserve asset, though it has previously explored decentralized clinical trials [1].

The market response to Windtree’s announcement has been cautiously optimistic. BNB’s 15% surge in the past month, driven by macroeconomic factors and speculative trading, has drawn attention to its potential as a corporate reserve. However, analysts warn that the purchase alone is unlikely to sustain long-term price stability, as the token remains subject to broader crypto market cycles [1].

The move underscores the growing intersection of traditional industries and digital assets. While pharmaceutical companies are not traditionally associated with crypto adoption, Windtree’s actions highlight a strategic shift toward viewing cryptocurrencies as alternative investments. Similar trends are emerging in fintech and real estate, where corporations are integrating crypto into portfolios. Yet, regulatory ambiguity and volatility remain critical challenges for institutional adoption [1].

Windtree’s commitment follows BNB’s surge to $808, a level not seen since late 2024. The firm’s purchase may temporarily boost investor confidence, but its long-term impact on BNB’s price will depend on broader market dynamics. The transaction also raises questions about how traditional investors perceive corporate crypto holdings—either as a competitive risk or a diversification opportunity. For now, the move serves as a case study in how corporations navigate the complexities of crypto markets, balancing innovation with risk management [1].

Source:

[1] [Decrypt] [https://decrypt.co/331894/drug-company-buy-700-million-bnb-all-time-high]

[2] [Investing.com] [https://www.investing.com/news/cryptocurrency-news]